STOCK TITAN

Legend Biotech Corporation (LEGN) Financials

LEGN NASDAQ
FY2025 annual
Revenue $1.0B +64.0% YoY
Net Income -$296.8M n/m YoY
EPS (Diluted) -$0.81 n/m YoY per ordinary share, about -$1.62 per ADS
Free Cash Flow -$128.8M n/m YoY
Market Cap $3.2B as of Nov 18, 2026
Price / Sales 3.1x on $1.0B revenue, FY2025
Price / Earnings n/m net loss, so no earnings multiple, FY2025
Price / Book 3.1x on $1.0B equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Earnings and dividends per share are per ordinary share, and share counts are in ordinary shares. LEGN trades in the US as American depositary shares (ADSs), and one ADS represents 2 ordinary shares.

Newest figures come from the 20-F for FY2025, filed Mar 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LEGN SEC filings page.

Legend Biotech Corporation (LEGN) reported $1.0B in revenue for fiscal year 2025, up 64.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Rhea AI LEGN FY2025

Revenue is scaling into better operating economics, but persistent losses and a sharper shift toward current liabilities keep cash conversion incomplete.

From FY2024 to FY2025, revenue rose 64.0% while R&D increased just 0.3%, indicating the research base was largely held steady as sales scaled. Operating loss narrowed, yet net margin slipped 0.6 percentage points, so operating progress did not flow through to bottom-line earnings.

Operating cash flow improved from -$144M to -$100.2M as revenue expanded, but cash generation still did not reach break-even. Capital expenditures rose from $14.1M to $28.6M, showing that reinvestment continued consuming cash even as operations improved.

Long-term debt fell from $250M to $0, removing that source of leverage. By FY2025, current liabilities were the dominant liability category, and the current ratio fell from 4.6x to 2.0x, indicating a much tighter short-term balance-sheet posture despite debt elimination.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 50 / 100
Financial Health Score 50/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Legend Biotech Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
15

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Legend Biotech Corporation scores 15/100 on it among other operating companies.

Growth
98

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Legend Biotech Corporation scores 98/100 on it among other operating companies.

Leverage
98

Legend Biotech Corporation carried $0.00 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 0.00. With no EBITDA figure for fiscal year 2025, Legend Biotech Corporation is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 98/100 among other operating companies measured the same way.

Liquidity
58

Legend Biotech Corporation held $1.96 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.96. Liquidity ranks operating companies on that ratio, and Legend Biotech Corporation scores 58/100 among other operating companies.

Cash Flow
6

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Legend Biotech Corporation scores 6/100 on it among other operating companies.

Returns
27

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Legend Biotech Corporation scores 27/100 on it among other operating companies.

Piotroski F-Score Weak
3/9

Legend Biotech Corporation passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing
N/A

Legend Biotech Corporation reported a net loss of $296.8M while operations used $100.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Legend Biotech Corporation reported an operating loss of $136.5M against $21.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$306.5M
YoY+64.3%
QoQ+12.5%

Legend Biotech Corporation generated $306.5M in revenue in Q4 2025. This represents an increase of 64.3% from the same quarter a year earlier. Against the prior quarter it is up 12.5%.

Net Income
-$30.8M
YoY-217.2%
QoQn/m

Legend Biotech Corporation reported a net loss of $30.8M in Q4 2025. This represents a decrease of 217.2% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.09
YoY-212.5%
QoQn/m

Legend Biotech Corporation earned -$0.09 per diluted ordinary share (EPS) in Q4 2025. This represents a decrease of 212.5% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EBITDA

Not reported for Q4 2025.

Cash & Balance Sheet

Free Cash Flow
-$24.6M
YoYn/m
QoQ-203.3%

Legend Biotech Corporation recorded an outflow of $24.6M in free cash flow in Q4 2025, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 203.3%.

Cash & Debt
$901.9M
YoY+214.6%
QoQ+223.4%
5Y CAGR+14.6%

Legend Biotech Corporation held $901.9M in cash against $0 in long-term debt as of Q4 2025.

Shares Outstanding
370M
YoY+0.7%
QoQ0.0%

Legend Biotech Corporation had 370M ordinary shares outstanding in Q4 2025. This represents an increase of 0.7% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

Gross Margin
61.0%
YoY-1.8pp
QoQ+2.6pp

Legend Biotech Corporation's gross margin was 61.0% in Q4 2025, indicating the percentage of revenue retained after direct costs. This is down 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.6 percentage points.

Net Margin
-10.1%
YoY-24.1pp
QoQ+4.5pp

Legend Biotech Corporation's net profit margin was -10.1% in Q4 2025, showing the share of revenue converted to profit. This is down 24.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.5 percentage points.

Return on Equity
-3.1%
YoY-5.6pp
QoQ+0.8pp

Legend Biotech Corporation's quarterly ROE was -3.1% in Q4 2025: one quarter's net income over shareholder equity, not annualized. This is down 5.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.

Operating Margin

Not reported for Q4 2025.

Capital Allocation

R&D Spending
$101.3M
YoY-2.9%
QoQ-10.4%

Legend Biotech Corporation invested $101.3M in research and development in Q4 2025. This represents a decrease of 2.9% from the same quarter a year earlier. Against the prior quarter it is down 10.4%.

Capital Expenditures
$12.4M
YoY+421.2%
QoQ+147.1%

Legend Biotech Corporation invested $12.4M in capex in Q4 2025, funding long-term assets and infrastructure. This represents an increase of 421.2% from the same quarter a year earlier. Against the prior quarter it is up 147.1%.

Share Buybacks

Not reported for Q4 2025.

LEGN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

Earnings and dividends per share are per ordinary share, and share counts are in ordinary shares. LEGN trades in the US as American depositary shares (ADSs), and one ADS represents 2 ordinary shares.

LEGN quarterly income statement
MetricQ4'2520-FQ3'256-KQ2'256-KQ1'256-KQ4'2420-FQ3'246-KQ2'246-KQ1'246-K
Revenue$306.5M+64.3%$272.3M+70.0%$255.1M+36.7%$195.1M+107.5%$186.5M$160.2M$186.5M$94.0M+158.7%
Cost of Revenue$119.5M+72.1%$113.3M+115.7%$94.9M+109.2%$69.5M+41.5%$69.4M$52.5M$45.4M$49.1M+37.9%
Gross Profit$187.0M+59.7%$159.1M+47.7%$160.2M+13.5%$125.6M+179.7%$117.1M$107.7M$141.2M$44.9M+6108.9%
R&D Expenses$101.3M-2.9%$113.1M+18.5%$98.3M-12.7%$101.9M+1.0%$104.4M$95.5M$112.6M$101.0M+18.9%
Operating IncomeN/A-$43.5Mn/mN/AN/A-$79.3M-$70.4MN/AN/A
Interest Expense$6.7M+64.2%$5.6M+2.4%$5.2M-4.8%$5.1M-7.6%$4.1M$5.5M$5.5M$5.5M+7.1%
Income Tax$11.2M-21.2%$616K-86.1%$582K+157.5%$1.8M+35620.0%$14.2M$4.4M$226K$5K-96.1%
Net Income-$30.8M-217.2%-$39.7Mn/m-$125.4Mn/m-$100.9Mn/m$26.3M-$125.3M-$18.2M-$59.8Mn/m
EPS (Basic)-$0.09-212.5%-$0.11n/m-$0.34n/m-$0.27n/m$0.08n/m-$0.34-$0.05-$0.16n/m
EPS (Diluted)-$0.09-212.5%-$0.11n/m-$0.34n/m-$0.27n/m$0.08n/m-$0.34-$0.05-$0.16n/m
Diluted Shares (Avg)N/A369M+0.7%368M+0.8%N/AN/A367M365MN/A

Not reported in any period shown, so not listed: SG&A Expenses, EBITDA.

LEGN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LEGN quarterly balance sheet
MetricQ4'2520-FQ3'256-KQ2'256-KQ1'256-KQ4'2420-FQ3'246-KQ2'246-KQ1'246-K
Total Assets$1.7B+3.8%$1.7B-1.3%$1.7B-6.0%$1.6B-9.0%$1.7B-9.7%$1.7B-5.6%$1.8B-6.9%$1.8B
Current Assets$1.2B-2.9%$1.2B-8.0%$1.2B-12.3%$1.2B-13.8%$1.3B-14.3%$1.4B-10.5%$1.4B-11.7%$1.4B
Cash & Equivalents$901.9M+214.6%$278.9M-39.3%$266.6M+32.5%$441.7M-50.8%$286.7M-77.6%$459.3M-52.3%$201.3M-83.7%$897.6M+36.0%
Inventory$32.0M+33.9%$29.2M+23.9%$35.6M+88.6%$30.9M+39.7%$23.9M+23.0%$23.5M+30.7%$18.9M+24.2%$22.1M
Total Liabilities$731.6M+16.2%$701.7M+13.2%$654.4M+2.4%$597.9M-2.2%$629.6M+5.4%$619.7M+24.0%$639.2M+22.1%$611.0M
Current Liabilities$636.4M+129.2%$433.6M+60.1%$265.5M-9.8%$234.4M-6.1%$277.7M+28.3%$270.9M+54.6%$294.3M+46.1%$249.7M
Non-Current Liabilities$95.2M-72.9%$268.1M-23.1%$388.9M+12.8%$363.5M+0.6%$351.9M-7.6%$348.8M+7.5%$344.9M+7.0%$361.4M
Long-Term Debt$0-100.0%$171.9M-42.0%$310.3M+6.4%$305.7M+6.8%$250.0M-11.1%$296.6M+7.5%$291.6M+7.7%$286.4M
Total Equity$1.0B-3.7%$1.0B-9.4%$1.0B-10.7%$1.0B-12.6%$1.0B-16.8%$1.1B-16.7%$1.2B-17.6%$1.2B+78.2%

Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Goodwill, Retained Earnings.

LEGN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LEGN quarterly cash flow statement
MetricQ4'2520-FQ3'256-KQ2'256-KQ1'256-KQ4'2420-FQ3'246-KQ2'246-KQ1'246-K
Operating Cash Flow-$12.2Mn/m$28.8Mn/m-$13.0Mn/m-$103.8M-768.6%-$82.0Mn/m-$75.8Mn/m-$1.7Mn/m$15.5Mn/m
Capital Expenditures$12.4M+421.2%$5.0M+142.4%$9.2M+169.8%$2.0M-67.9%$2.4M-45.4%$2.1M-61.6%$3.4M-43.8%$6.2M+46.1%
Free Cash Flow-$24.6Mn/m$23.8Mn/m-$22.3Mn/m-$105.8M-1240.2%-$84.4Mn/m-$77.9Mn/m-$5.1Mn/m$9.3Mn/m
Investing Cash Flow$638.5Mn/m-$20.0M-106.1%-$165.5Mn/m$256.6Mn/m-$87.9M-121.6%$329.1Mn/m-$695.6Mn/m-$396.1M-2571.0%
Financing Cash Flow-$647Kn/m$670K-84.2%-$990K-203.7%$667K-19.7%-$331K-135.8%$4.2M+341.7%$955K-99.9%$831Kn/m

Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.

LEGN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LEGN quarterly financial ratios
MetricQ4'2520-FQ3'256-KQ2'256-KQ1'256-KQ4'2420-FQ3'246-KQ2'246-KQ1'246-K
Gross Margin61.0%-1.8pp58.4%-8.8pp62.8%-12.9pp64.4%+16.6pp62.8%67.2%75.7%47.8%+45.8pp
Operating MarginN/A-16.0%+28.0ppN/AN/A-42.5%-43.9%N/AN/A
Net Margin-10.1%-24.1pp-14.6%+63.7pp-49.2%-39.4pp-51.7%+11.9pp14.1%-78.2%-9.8%-63.6%
Return on Equity-3.1%-5.6pp-3.9%+7.3pp-12.1%-10.5pp-9.9%-4.8pp2.5%-11.2%-1.6%-5.1%+12.0pp
Return on Assets-1.8%-3.4pp-2.3%+4.9pp-7.4%-6.4pp-6.3%-2.9pp1.6%-7.2%-1.0%-3.4%
Current Ratio1.96-2.7x2.86-2.1x4.71-0.1x5.20-0.5x4.62-2.3x4.98-3.6x4.84-3.2x5.66
Debt-to-Equity0.00-0.2x0.17-0.1x0.300.0x0.30+0.1x0.240.0x0.27+0.1x0.25+0.1x0.25
Liabilities-to-Equity0.73+0.1x0.69+0.1x0.63+0.1x0.59+0.1x0.61+0.1x0.56+0.2x0.55+0.2x0.52
Asset Turnover0.18+0.1x0.16+0.1x0.150.0x0.12+0.1x0.110.090.100.05
FCF Margin-8.0%+37.2pp8.7%+57.4pp-8.7%-6.0pp-54.2%-64.1pp-45.3%-48.6%-2.7%9.9%

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Legend Biotech Corporation LEGN FY2025 $1.0B -$296.8M -28.8% $3.2B 50/100
Iovance Biotherapeutics, Inc. IOVA FY2025 $263.5M -$391.0M N/A $3.5B 62/100
Viridian Therapeutics, Inc. VRDN FY2025 $70.8M -$342.6M N/A $3.4B 69/100
Acadia Pharmaceuticals Inc. ACAD FY2025 $1.1B $391.0M 36.5% $3.1B 68/100
Zai Lab Limited ZLAB FY2025 $460.2M -$175.5M -38.1% $2.8B 67/100
AbCellera Biologics Inc. ABCL FY2025 $75.1M -$146.4M N/A $3.6B 54/100

Frequently Asked Questions

Legend Biotech Corporation (LEGN) reported $1.0B in total revenue for fiscal year 2025. This represents a 64.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Legend Biotech Corporation (LEGN) revenue grew by 64.0% year-over-year, from $627.2M to $1.0B in fiscal year 2025.

No, Legend Biotech Corporation (LEGN) reported a net loss of $296.8M in fiscal year 2025, with a net profit margin of -28.8%.

Legend Biotech Corporation (LEGN) reported diluted earnings per share of -$0.81 per ordinary share for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis. Earnings and dividends per share are per ordinary share, and share counts are in ordinary shares. LEGN trades in the US as American depositary shares (ADSs), and one ADS represents 2 ordinary shares.

As of fiscal year 2025, Legend Biotech Corporation (LEGN) had $901.9M in cash and equivalents against $0 in long-term debt.

Legend Biotech Corporation (LEGN) had a gross margin of 61.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Legend Biotech Corporation (LEGN) had an operating margin of -13.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Legend Biotech Corporation (LEGN) had a net profit margin of -28.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Legend Biotech Corporation (LEGN) has a return on equity of -29.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Legend Biotech Corporation (LEGN) recorded an outflow of $128.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Legend Biotech Corporation (LEGN) recorded an outflow of $100.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Legend Biotech Corporation (LEGN) had $1.7B in total assets as of fiscal year 2025, including both current and long-term assets.

Legend Biotech Corporation (LEGN) invested $28.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Legend Biotech Corporation (LEGN) invested $414.7M in research and development during fiscal year 2025.

Legend Biotech Corporation (LEGN) had 370M ordinary shares outstanding as of fiscal year 2025.

Legend Biotech Corporation (LEGN) had a current ratio of 1.96 as of fiscal year 2025, which is generally considered healthy.

Legend Biotech Corporation (LEGN) had a debt-to-equity ratio of 0.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Legend Biotech Corporation (LEGN) had a liabilities-to-equity ratio of 0.73 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Legend Biotech Corporation (LEGN) had a return on assets of -17.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Legend Biotech Corporation (LEGN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $3.2B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Legend Biotech Corporation (LEGN) trades at 3.1x sales, its market capitalization divided by $1.0B revenue, FY2025. The market capitalization is $3.2B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Legend Biotech Corporation (LEGN) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Legend Biotech Corporation (LEGN) reported a net loss of $296.8M while operations used $100.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Legend Biotech Corporation (LEGN) reported an operating loss of $136.5M against $21.4M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Legend Biotech Corporation (LEGN) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top